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Abstract. It is well known that tumors originating from the same tissue have dif-
ferent prognosis and sensitivity to treatments, depending on their molecular features.
Over the last decade, cancer genomics consortia like the Cancer Genome Atlas (TCGA;
https://cancergenome.nih.gov) have been generating thousands of cross-sectional data,
spanning from genetic and epigenetic mutations to proteome profiles, for thousands of
human primary tumors originated from various tissues. Thanks to the public access pro-
vided by such consortia to their datasets, it is today possible to analyze a broad range
of relevant information such as gene sequences, expression profiles or metabolite foot-
prints, to capture tumor molecular heterogeneity and improve patient stratification and
clinical management. To this aim, it is common practice to analyze datasets grouped
into clusters based on clinical observations and/or molecular features. However, the
identification of specific properties of each cluster that may be effectively targeted by
therapeutic drugs still represents a challenging task. In this perspective, characteriza-
tion of the metabolism of stratified patient cohorts may greatly help to select the best
pharmacological treatment to prevent biomass formation and hence tumor growth. In
this work, we define a method to generate an activity score for the metabolic reactions
of different clusters of patients based on their transcriptional profile. This approach
reduces the number of variables from many genes to few reactions, by aggregating tran-
scriptional information associated to the same enzymatic reaction according to gene-
enzyme and enzyme-reaction rules. As a proof of concept, we applied the methodology
to a dataset of 244 RNAseq transcriptional profiles taken from patients with colorectal
cancer (CRC), the second cause of cancer death in USA. CRC samples are typically
divided into two sub-types: (i) tumors with microsatellite instability (MSI), associated
with hyper-mutation and with CpG island methylation phenotype, and (ii) microsatellite
stable (MSS) tumors, typically endowed with chromosomal instability. We report some
key differences in the central carbon metabolism of the two clusters. We also show how
the method can be used to describe the metabolism of individual patients and cluster
them exclusively based on metabolic features.
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1 Scientific Background
Genome-wide reconstructions of human metabolism, such as HMR [1] and Recon
2.2 [2], are today available. These models include most metabolic reactions that may
occur in a generic cell. To analyze a given tissue is necessary to extract a specific sub
model with the subset of reactions that actually occur. Several methodologies have
been proposed to reach this goal using transcriptome, proteome or even metabolome
data [3, 4]. These methodologies require to set a threshold of gene expression or protein
level whereby to decide whether keeping or removing a pathway. This partially arbitrary
parameter deeply affects the extracted model [3].
The above mentioned stoichiometric models are conceived to perform Flux Bal-
ance Analysis (FBA): a technique that exploits linear programming to compute the flux
through each reaction under a steady state assumption [5]. The advantage of FBA is
its use without knowledge about the enzymatic kinetic constants. FBA is based on the
maximization (or minimization) of a given objective function. To simulate growth of
tumor cells, maximization of biomass production is typically assumed. To perform a
correct FBA it is necessary to define the nutritional constrains, i.e., the incoming nutri-
ents and the outcoming products (exchange reactions). Unluckily this kind of data are
yet rare in public databases.
For these reasons, gene expression data are most often analyzed with gene set enrich-
ment analysis algorithms. For instance, PANTHER classifies genes according to their
function in several different ways: families and subfamilies are annotated with ontology
terms [6]. Nevertheless these algorithms do not account for the fact that metabolic re-
actions may be catalyzed by multi-domain enzymes or by different protein isoforms, as
this would require knowledge on how genes are linked to enzymes. Association rules,
which might now be retrieved from metabolic models, would provide more refined in-
formation than a mere list of genes.
Along similar lines, metabolic reporter analyses, try to provide knowledge about
variations in metabolite concentrations, starting from sets of genes classified according
to the metabolite they associate with [7]. However these algorithms do not provide
information about which reactions are up or down regulated, and thus on the putative
targets for cancer treatment. Indeed reaction rates and metabolite concentrations are
difficult to correlate.
We propose a methodology to infer deregulations of metabolic reactions, which, as
opposed to FBA, does not need exometabolomic information nor optimality assump-
tions, but it simply takes as input transcriptomic profiles. For each reaction, we resolve
the gene rules and compute a score as a function of the transcript level. Thus it is not
necessary to set a threshold a priori. We do not perform FBA simulations, but we only
consider these scores as a static representation of the metabolic behavior of the given
dataset. The methodology provides clear and useful information about which set of
reactions are over (or under) expressed.
We apply the methodology to the manually reconstructed core model HMRcore –
previously tested in [8, 9] – which contains pathways and reactions of central carbon
metabolism extracted from the HMR genome-wide model [1] and the corresponding
gene rules extracted from Recon 2.2 [2].
2 Materials and Methods
In this, work we started from the HMRcore model and from a dataset of colorectal
cancer (CRC) downloaded from TCGA [10]. For the sake of completeness, we included
in the model mitochondrial palmitate degradation and gluconeogenesis. In total we have
229 reactions with rules and 375 metabolic genes associate to them. We took gene rules
from Recon2.2, where genes are identified with HGNC ID provided by the HUGO Gene
Nomenclature Committee. Because each dataset identifies genes with different IDs we
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coded a script that automatically convert HGNC to any other ID.
The dataset under study contains level 3 RNAseq-v2 of CRC tissue samples gathered
from 244 patients. Each tumor sample was already classified as MSS or MSI. We relied
on this supervised classification to characterize with our method the two tumor subtypes.
We represented our dataset in the from of a ng × np matrix G, where ng is the total
number of genes and np is the number of patients. Each element Gg,p is the RPKM
(reads per kilobase per milion mapped reads) of gene g in patient p which is a proxy for
the transcript level. We retain only the rows of this matrix corresponding to genes that
are associated to reactions in the HMRcore model and used this new matrix as input for
our algorithm.
Gene-enzyme rules are logical formulas that define the gene products a given reaction
is catalyzed by and their relationship. These relationships are described by the logical
operators AND and OR. The former defines set of genes that transcribe for different
enzymatic sub units, which are all necessary for catalytic activity. The latter defines
instead genes that transcribe for protein isoforms of the same enzyme, so that either
one of them is sufficient to catalyze the reaction. For example the succinate-CoA ligase
enzyme is formed by the subunit alpha (gene SUCLG1) and beta gene (SUCLG2) and
catalyzes the reaction Pi+ succinyl-CoA+GDP1↔ CoA+ succinate+GTP . The
gene-enzyme rule for this reaction is therefore: SUCLG1 AND SUCLG2. Conversely,
ACACA and ACACB are respectively fully functional enzyme for the reaction acetyl-
CoA carboxylase, thus the rule is ACACA OR ACACB.
These logical operators can of course be combined to depict multi protein catalytic
complexes or more complex situations involving both subunits and isoforms. For in-
stance, ribonucleotide reductase is formed by two subunits: the catalytic (M1) and the
regulatory one. The latter exists in two isoforms (M2 and M2B). The rule for this en-
zyme will therefore be RRM1 AND (RRM2 OR RRM2B).
To avoid the definition of a threshold and to be able to associate a continuous value to
each reaction in different clusters, our method does not resolve the logical expressions
in a Boolean fashion. We rather sum the transcripts of genes associated with the OR
operator, whereas we take the minimum transcript of genes associated with the operator
AND by respecting the precedence of the two operators. We thus obtain a score for each
reaction in each patient.
The final output is therefore a nr × np matrix S where each element Sr,p is the score
computed for reaction r in patient p.
We split matrix S into two sub-matrixes according to tumor subtype classification.
For each reaction we then test if the distribution of its scores is significantly different in
the two clusters – with the non parametric two-sample Kolmogorov-Smirnov test – with
a p-value threshold of 0.05. For every reaction that passed the test, we calculated the
log2 fold change of the average score of that reactions in the two clusters. Because KS-
test considers as significantly different distributions with the same mean but different
standard deviation, we consider as relevant only log2 fold change greater than 0.263
(corresponding to a 20% variation in the average score).
3 Results
We applied our method to explain, in terms of metabolic behavior, the differences
between MSS tumors, which typically show worse prognosis, and less common MSI
tumors, showing tumour-infiltrating lymphocytes and a better prognosis. We took the
gene expression profiles and computed the reactions score as described in the previous
section. To better visualize the results of our analyses, we drew the fold change of each
reaction on the map in Fig.1.
The pathways more or less expressed in MSI with respect to MSS can be easily
observed. For example three reactions in glycolysis pathway have a higher score in MSI
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respect to MSS. When comparing the two colorectal cancer subtypes (MSI versus MSS)
we indeed observed that the former is more glycolytic and, remarkably, it prefers to use
NAD+ as cofactor to catalyze malate dehydrogenase reaction, whereas MSS prefers the
NADP+ dependent reaction.
Figure 1: Map of HMRcore with fold change of reaction scores drawn on it. Red arrows refer to reactions
upregulated in MSI; whereas blue arrows refer to reactions upregulated in MSS. Black arrows refer to
Not Classified reactions, i.e., reactions without information about the corresponding gene-enzyme rule.
Dashed gray arrows refer to non significant deregulations according Kolgorov-Smirnof test. Solid gray
arrows refer to reactions with a log2 fold change below 0.263
It can be observed that most reactions are not significantly different, suggesting that
sharp metabolic differences in central carbon metabolism do not stand out, as long as
this classification of patients is considered. On the one hand, our tool could be used to
evaluate which existing partitions better highlight such differences. On the other hand,
it could be directly used to identify new cluster of patients that maximize the metabolic
differences among them, by performing an unsupervised cluster analysis on the scores
that have been calculated for each patient.
As a first approximation, we executed a k-means clustering on the reactions score
obtained with our algorithm in order to split the dataset into two clusters (k = 2). We
refer to these new clusters as A and B. Based upon the new obtained classification, we
repeated the procedure described before. As expected, the new obtained map (Fig.2)
shows greater differences between the two metabolisms. Interestingly, it is evident that
one group with respect to the other shows a metabolism with more highly expressed
glycolysis, fatty acid production from a reductive metabolism of glutamine, but a less
expressed electron transport chain and oxidative phosphorylation. We remark that even
though glycolysis is higher, the mitochondrial uptake of pyruvate is less expressed, in-
dicating a lower oxidation of glucose, which is probably fermented to lactate.
It is worth noticing that although the two clusters have different cardinality (29 and
215 for cluster A and B respectively) the Kolmogorov-Smirnov hypothesis test should
not be affected. Indeed, our results are confirmed even when we repeated the analysis
considering the same cardinality for the two groups, i.e., by randomly selecting only 29
members from cluster B.
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Figure 2: Map of HMRcore with fold change of reactions scores drawn on it. Red arrows refer to reactions
up-regulated in cluster A; whereas blue arrows refer to reactions up-regulated in cluster B. Black arrows
refer to Not Classified reactions, i.e., reactions without information about the corresponding gene-enzyme
rule. Dashed gray arrows refer to non significant deregulations according Kolgorov-Smirnof test. Solid
gray arrows refer to reactions with a log2 fold change below 0.263
In order to highlight the novelty of the results than can be obtained with our algo-
rithm, we also performed the widely used Gene Set Enrichment Analysis (GSEA) on
the same dataset. We considered each reaction as a different gene set that includes the
genes associated with that reaction. We considered as phenotypes MSS and MSI, so the
input was exactly the same used before. We used a desktop application [11] to run the
analysis. GSEA couldn’t extract any significant result probably because a lot of get sets
contain just one or few genes. All in all, our method is able to obtain more information
and with a higher resolution as compared with a GSEA on the same dataset.
4 Conclusion
We introduced a method that computes a score for each metabolic reaction, starting
from transcriptome profiles. The quality of our results depends on the correctness of the
gene-enzyme rules. As we took them from Recon2.2 as they were, our results might be
improved by manually curating such rules.
In conclusion, our method is able to extract important information starting from any
transcriptomics dataset, by reducing the dataset dimensionality from thousand genes to a
smaller number of reactions. The analysis focuses on the metabolic genes encompassed
in a given metabolic network model. We limited the analysis to central carbon pathways.
In the next future we will extend the analysis to a genome wide model in order to show
all the metabolic differences between tumors.
Finally, by clustering the scores obtained from clinical data, our method paves the
way to easily linking particular prognosis or tumor aggressiveness to different metabolic
traits.
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